Biolegend, 135202, Purified anti-mouse CD279 (PD-1) Antibody, 500μg

CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.
500μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/mL
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: FC - Quality tested IHC-F - Verified Block - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.
Application References(PubMed link indicates BioLegend citation): Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block) Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block) Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Peymanfar Y, et al. 2023. Int J Mol Sci. 24:. PubMed Morales-Molina A, et al. 2020. Cancers (Basel). 12:. PubMed Kobayashi A, et al. 2021. Front Immunol. 12:650856. PubMed Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed Jiang W, et al. 2021. Sci Rep. 11:1864. PubMed Avalos A, et al. 2022. JCI Insight. 7: . PubMed Mugarza E, et al. 2022. Sci Adv. 8:eabm8780. PubMed Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed Potempa M, et al. 2022. J Immunol. 208:1742. PubMed Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed Chartrand K, et al. 2018. Front Immunol. 1.642361111. PubMed Shirakawa K, et al. 2017. PLoS One. 12:e0186303. PubMed Ajona D, et al. 2017. Cancer Discov. 0.773611111. PubMed Goel S, et al. 2017. Nature. 548:471. PubMed Wang W, et al. 2018. Cancer Cell. 34:757. PubMed Wang J, et al. 2021. Cancers (Basel). 13:. PubMed Imazeki H, et al. 2021. J Immunother Cancer. 9:. PubMed Carpenter SM, et al. 2017. PLoS Pathog. 13:e1006704. PubMed Haque M, et al. 2021. Viruses. 13:. PubMed Son YM, et al. 2020. Eur J Immunol. 50:1067. PubMed Wang Y, et al. 2021. Cancer Cell. 39:1375. PubMed Xie MM, et al. 2017. Eur J Immunol. 47:1136. PubMed Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed Muhammad F, et al. 2020. Front Immunol. 975:11. PubMed Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed Wang J, et al. 2017. Cancer Prev Res (Phila). 10:684. PubMed Fiege JK, et al. 2019. PLoS Pathog. 15:e1008077. PubMed Hilligan KL, et al. 2020. Nat Commun. 11:5637. PubMed Oba T, et al. 2021. J Immunother Cancer. 9:. PubMed Sato Y, et al. 2021. BMC Cancer. 21:1222. PubMed Huang B, et al. 2015. PLoS One. 10: 0134715. PubMed Kinosada H, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006120. PubMed Gilfillan CB, et al. 2020. Eur J Immunol. 50:505. PubMed Karmaus PWF, et al. 2019. Nature. 565:101. PubMed Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed Flietner E, et al. 2022. Sci Rep. 12:10616. PubMed Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed Wang M, et al. 2022. Front Pharmacol. 13:887457. PubMed Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed
RRID: AB_1877121 (BioLegend Cat. No. 135202)
Structure: A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
Distribution: Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.
Function: Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
Ligand/Receptor: B7-H1 (PD-L1) and B7-DC (PD-L2)
Cell Type: B cells, T cells
Biology Area: Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family: CD Molecules, Immune Checkpoint Receptors
Antigen References: 1. Nishimura H, et al. 2001. Science 291:319 2. Agata Y, et al. 1996. Int. Immunol. 8:765 3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706 4. Barber DL, et al. 2006. Nature 439:682 5. Keir ME, et al. 2005. J. Immunol. 175:7372 6. Koehn BH. et al. 2008. J Immunol. 181:5313
Gene ID: 18566
UniProt: View information about CD279 on UniProt.org
Clone: 29F.1A12
Regulatory Status: RUO
Other Names: PD-1, Programmed Death-1, PDCD1
Isotype: Rat IgG2a, κ